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Toward a Better Understanding of...
ROCK Inhibitors Prevent DLK Activation 
in a Regenerative Context
Trevor J. Krolak
Mentor: Aaron DiAntonio
During development, neurons extend axons across great distances to form a neural 
network. However, the length of axons makes them vulnerable to injury and disease. 
Following injury, axons degenerate and must be regrown to restore function.
In the central nervous system, regeneration fails completely. By contrast, in the 
peripheral nervous system, neurons activate a regenerative response that is capable of 
achieving limited regrowth. In severe cases, however, this regeneration is insufficient 
for functional recovery. If the regenerative program could be induced or sustained 
pharmacologically, functional recovery would be more obtainable.
The DiAntonio laboratory has previously demonstrated that Dual Leucine Zipper 
Kinase (DLK), a stress-induced MAP triple kinase, is required for activation of the 
regenerative program following injury. However, the regulatory mechanisms governing 
DLK remain poorly understood.
Using an in vitro assay of DLK activity, we demonstrated that ROCK inhibitors 
(ROCKi) could block cytoskeletal stress-induced, DLK-dependent regenerative signaling. 
Because DLK signaling plays an important role in other aspects of the neuronal injury 
response, including axon degeneration and cell death, we examined the ability of ROCKi 
to influence these responses. Treatment with the inhibitors did not affect cell death or 
axon degeneration, suggesting that their capacity to regulate DLK activity is restricted to 
a regenerative context.
Ultimately, our work has identified novel pharmacological regulators of DLK, a 
kinase required for activation of the regenerative program, and interrogated their 
mechanism. An expanded understanding of the program’s regulatory mechanisms will 
provide therapeutic targets to combat neurodegenerative disease and injury.
